SUMMARY Background
Per-oral tacrolimus administration is not always practicable. Sublingual administration is a potential alternative, but its feasibility and effectiveness compared with oral route has not been established.
Aim
To compare tacrolimus drug exposure after sublingual and oral administration in liver transplant recipients.
Methods
Experimental, open-label, non-randomised, cross-over study. Tacrolimus exposure was evaluated in 32 liver transplant recipients receiving oral administration. 12 h tacrolimus area-under-the-curve (AUC 0-12 h ) was calculated using tacrolimus blood concentrations at 0-0.5-1-2-4-6-8-12 hrs post-dose. Recipients were switched to sublingual administration, and dose was adjusted to reach similar trough levels, new AUC 0-12 h was calculated. Correlation between AUC 0-12 h and trough levels was determined for both oral and sublingual phases.
Results
Similar trough levels were accomplished with oral and sublingual administration (6.68 AE 2 ng/mL vs. 6.62 AE 1.9 ng/mL (P = 0.8)). Although concentration 2 h post dose was higher in oral phase (15.36 AE 7.14 vs. 13.18 AE 5.64, P = 0.015), AUC 0-12 h was similar in both phases (116.6 AE 34.6 vs. 111.5 AE 36.93 ng/mL * h, P = 0.19). Daily dose of tacrolimus required in sublingual phase was 37% lower than that used in oral phase (P < 0.0001), suggesting significantly increased bioavailability of tacrolimus when employing sublingual route. Good correlation between AUC 0-12 h and trough levels was observed in sublingual phase (r 2 = 0.74). Twenty-two recipients were maintained on sublingual administration after the end of study (mean follow-up: 18.7 AE 5.8 months). No difference in liver function tests or rejection rates was found during follow-up period.
Conclusions
Sublingual administration of tacrolimus is feasible and provides similar drug exposure compared with oral administration. In our study, at long-term follow-up, sublingual administration was not associated with liver transplant rejection. Moreover, containers and administration sets must be polyvinyl chloride-free since tacrolimus, as a lipophilic compound, can be adsorbed to polyvinyl chloride, and the extraction of toxic phthalates has been reported when it is combined with polyvinyl chloride. Intravenous tacrolimus administration is also very expensive (ten-to fifteen-fold more expensive than oral administration in our centre). Alternative routes have been explored. Amongst them, sublingual (SL) administration has been reported in six studies since 2001. [6] [7] [8] [9] [10] [11] [12] However, most were small, uncontrolled retrospective studies and did not evaluate the total exposure to tacrolimus. One of these studies included liver transplant recipients, although it included only six patients.
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The results of the existent trials are not consistent. Two of them found similar area under the concentration-time curves (AUCs), 6 , 11 but other studies were not able to find detectable tacrolimus concentrations after SL administration. 9, 10 Hence, the feasibility of tacrolimus SL administration and its ability to provide similar drug exposure compared with PO administration is not clear. The aim of this study was to evaluate the feasibility of SL administration and to compare tacrolimus drug exposure after SL and PO administration in liver transplant recipients.
MATERIALS AND METHODS
Patients
Liver transplant recipients at least 12 months after transplantation were recruited. Inclusion criteria were: adult liver recipients, tacrolimus-based immunosuppression scheme (manufactured by Sandoz, Holzkirchen, Germany), absence of rejection during the last 6 months, absence of drugs that interfere with tacrolimus metabolism (i.e., azole antifungal drugs, nifedipine, diltiazem, macrolides, etc.), ability to follow instructions, and signed informed consent. Exclusion criteria included use of an extended release tacrolimus formulation, need for immediate change of tacrolimus dose, and adverse effects that precluded continuation of tacrolimus administration.
Design
This was an open-label, nonrandomized, cross-over assignment treatment study of tacrolimus pharmacokinetics/dynamics in liver transplant recipients. Patients were on PO tacrolimus administration with a stable dose for at least 2 months. Tacrolimus blood concentrations were evaluated on an Architect i1000 SR immunoassay analyser, Abbott Laboratories (Lake Bluff, Illinois, IL, USA) at 0, 0.5, 1, 2, 4, 6, 8 and 12 h after tacrolimus administration (PO phase).
After the PO administration studies, the patients were switched to SL administration, and the tacrolimus dose was tapered to get similar trough levels (difference not exceeding 1.5 ng/mL from the trough level of the oral phase). If the SL dose was changed, at least 7 days elapsed before the next tacrolimus trough level. Once trough levels similar to the PO phase were achieved in the SL phase, a second pharmacokinetic study was performed during the next one to 4 weeks (SL phase) (Figure 1) .
For SL administration, the tacrolimus capsule was opened and the powder content of the regular tacrolimus capsule was placed under the tongue. The patient was instructed not to swallow until the powder was completely dissolved to maximise the SL absorption.
Pharmacokinetic study
Trough level, maximum concentration (C max ) and time to C max (T max ) were determined. Drug exposure was evaluated employing 12 h area-under-the-curve (AUC 0-12 h ) calculated with the trapezoid method using GraphPad Prism. v6.0 (San Diego, CA, USA).
Statistical analysis
Descriptive statistics (i.e., means, medians, standard deviations, interquartile ranges, proportions) were performed to assess the study sample characteristics. Differences were evaluated employing Student's t-test or Wilcoxon matched pairs test for quantitative data between groups. Furthermore, 95% confidence intervals were calculated whenever appropriate. Linear regression by the Pearson correlation between dose and trough levels was expressed as r 2 . A two-tailed P-value of less than 0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism v6.0 (San Diego, CA, USA). The study protocol was conducted in accordance with the Helsinki Declaration and approved by the Ethics Committee of our centre. ClinicalTrials.gov identifier: NCT02608606. Table 1 depicts the main characteristics of the patients enrolled. Importantly, all patients were evaluated on an ambulatory basis. The time elapsed from switching to SL administration to obtaining similar trough levels as in the PO phase was 80.0 AE 52.47 days.
RESULTS
Patients characteristics
Pharmacokinetic study Similar trough levels (mean AE s.d.) were obtained in the PO and SL phases: 6.68 AE 2 ng/mL vs. 6.62 AE 1.9 ng/mL (P = 0.8). C max was statistically higher in the PO vs. the SL phase: 18.24 AE 9.16 vs. 14.47 AE 6.48, respectively (P = 0.007). T max was 1.98 AE 1.1 h for PO vs. 1.73 AE 0.9 h for SL (P = 0.23). Differences in concentrations at different time points in the PO and SL phases are shown in Figure 2 . It should be noted that C 2 was statistically higher in the PO phase: 15.36 AE 7.1 vs. 13.18 AE 5.6 (P = 0.015).
Even considering the significant difference on C 2 , tacrolimus AUC 0-12 h was similar for both PO and SL administration (116.6 AE 34.6 vs. 111.5 AE 36.9 ng/mL * h, P = 0.19) (Figure 3) .
Correlation between tacrolimus dose (mg/kg) and AUC 0-12 h was poor, although it was similar for both the PO and SL routes (r 2 = 0.22 vs. Similar trough levels (mean AE s.d.) were obtained in the PO and SL phases: 6.68 AE 2 ng/mL vs. 6.62 AE 1.9 ng/mL (P = 0.80). C max was statistically higher in the PO phase vs. the SL phase: 18.24 AE 9.16 vs. 14.47 AE 6.48, respectively. *P = 0.007.
Interestingly, there was a proper correlation between trough levels and AUC 0-12 h in both groups: r 2 = 0.62 for tacrolimus PO and r 2 = 0.74 for tacrolimus SL (Figure 4c and d) , suggesting that tacrolimus exposure after SL administration could be properly monitored employing trough levels. Notably, the dose required to provide similar trough levels in both the groups was 37% lower in the SL phase (4.2 AE 1.99 mg/day vs. 2.64 AE 1.41 mg/day, P < 0.0001).
Sublingual administration seems to be effective in the long term Twenty-two of 32 patients (69%) continued with SL administration after the end of the study (mean follow-up 18.68 AE 5.84 months). Notably, none of these patients developed alterations in liver chemistry or a suspected or biopsy proven rejection, nor any other complication related to immunosuppression in the long term (Table 2) .
Adverse reactions
No severe adverse reactions were attributable to the study drug. However, 27 out of 32 patients reported mild and transient dysgeusia associated with spicy meals in the SL phase. One patient reported small blisters under the tongue that disappeared spontaneously. None of the patients needed to discontinue SL administration.
DISCUSSION
Although PO is the standard tacrolimus administration route because of its simplicity, tacrolimus is widely metabolised in the liver and small intestine by cytochrome P450 microsomal enzymes and P-glycoprotein, resulting in low bioavailability; relatively high doses are required to achieve an appropriate drug exposure. 4 The mucosa of the ventral surface of the tongue and the floor of the mouth is thinner than the buccal, gingival and palatal mucosa (approximately 100-200 micrometres), and since it is permanently lubricated by the secretions of the salivary glands, it allows passive diffusion of several drugs that reach systemic circulation via the facial veins, internal jugular and brachiocephalic veins. 13, 14 Sublingual administration has been proven to be efficacious for several drugs (i.e., nitroglycerine, captopril, ondansetron, and frusemide). When feasible, some of the most important advantages of SL administration include: (i) Rapid onset of action; (ii) Avoids enteral metabolism and liver first-pass effect; and (iii) Provides an alternative route to parenteral administration when enteral administration is not available.
14 Although there are a few studies and reports evaluating SL tacrolimus administration published over the last years, their results are inconsistent, do not always include transplant recipients, and the number of subjects evaluated is low. Thus, until now, the feasibility of SL tacrolimus administration has not been properly evaluated in transplant recipients.
Specifically, in the liver transplant setting, there is only one study including six patients. 11 In this study, patients received their morning dose orally on the first day and sublingually on the second day. Since this study evaluated the effect of a single dose, it does not allow for evaluation of whether the SL administration of tacrolimus provides consistently appropriate drug exposure and its long-term clinical efficacy. Hence, additional studies were warranted.
The aim of the present study was to evaluate the feasibility of SL tacrolimus administration and drug exposure compared with the PO administration in an open-label cross-over study including outpatients. In contrast to prior studies in liver transplant patients, we evaluated tacrolimus levels once similar trough levels were achieved, and we included long-term follow-up in 22 subjects. This study provides interesting results: (i) Sublingual administration seems to be feasible considering that appropriate trough levels were achieved and no severe side effects were reported; (ii) Tacrolimus exposure was comparable for PO and SL administration; (iii) There is an excellent correlation between AUC 0-12 h and trough level following SL administration, suggesting that trough levels can be safely used to perform therapeutic drug monitoring; (iv) The absence of rejection and important adverse effects during the long-term follow-up suggests that the SL route could be safe and clinically effective; (v) The SL route allows a significant reduction in tacrolimus dose with a consequent reduction in immunosuppression costs.
To the best of our knowledge, this is the largest study evaluating the feasibility and exposure to tacrolimus employing SL administration. It must be noted that several of the available studies are not controlled, most are retrospective, and some do not include transplant recipients.
We are aware of the limitations of our study, mainly: (i) It was not designed as a non-inferiority study but as a pilot experience. However, considering that the most important variable (AUC) is continuous, there was insufficient data in the published literature to estimate the standard deviation of the outcome. Therefore, until now, it was impossible to properly design a non-inferiority trial; (ii) This study did not include patients in the immediate post-transplant period (including those on mechanical ventilation or those with ileus). Hence, these results cannot necessarily be extrapolated to those patients who frequently require drugs that could interfere with the metabolism of tacrolimus. However, we think that, based on these results, a trial in patients in the immediate post-transplant period can now be performed to elucidate this point; (iii) Considering the design of our study, we cannot exclude enteral absorption of tacrolimus. In fact, we think that this is a very interesting and relevant point. Stifft et al. 9 conducted a study to evaluate the role of sublingual absorption, making an effort to exclude a significant contribution of enteral absorption. Accordingly, the subjects in the SL phase (no transplant recipients were included) were instructed to avoid swallowing and to rinse their mouth with water after a fifteen minute period, assuming that SL absorption is not significant after 15 min. Remarkably, most of the subjects in the SL tacrolimus administration phase showed no detectable concentrations. In our study, the fact that similar trough levels and drug exposure were achieved with both PO and SL administration with a significant dose reduction (37%) in the SL phase suggests that SL absorption contributes significantly to tacrolimus exposure, probably avoiding the first-pass effect and enteral metabolism, as has been reported in previous studies with similar findings. 6, 8, 11 Dose reductions in the SL phase can have significant economic implications. Thus, considering the mean dose employed by our patients, the cost of per-oral tacrolimus administration would be US $7727 per year compared with US$4855 employing SL administration, meaning a potential savings of US$2872 per patient every year. This is a relevant issue in several countries in which patients with private insurance are obligated to pay most or all of the cost of immunosuppressive drugs, creating a barrier to treatment compliance. On the other hand, those patients with public insurance receive support from a system with very scarce resources. Therefore, SL tacrolimus administration could save a significant amount of resources that could be used in other areas. The SL route could therefore be considered a more rational method of tacrolimus administration, especially taking into account the characteristics of some health systems. This issue could explain why 22 of our patients voluntarily chose to remain using SL tacrolimus. However, we are aware that this strategy might be considered unnecessary in countries with different financing of the health system where patients could consider PO administration a more comfortable option.
In conclusion, this is the largest study evaluating the feasibility, drug exposure and efficacy of SL tacrolimus administration in liver transplant recipients. Notably, SL administration achieved similar drug exposure to the PO route employing a significantly lower dose. The good correlation between trough levels and AUC 0-12 h on the SL phase suggest that trough levels can be safely used for monitoring tacrolimus exposure. Finally, our findings suggest that the SL route could be clinically effective (in terms of avoiding rejection) in the long term. To confirm our results, a non-inferiority trial should be conducted including a long-term follow-up to evaluate the clinical efficacy of this strategy.
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